In addition, the combination of IL-33 blockers with programmed death-1 monoclonal antibodies could successfully inhibit acute myeloid leukaemia, and its combination with imatinib could also prevent chronic myeloid leukaemia resistance [48]. This evidence concerns the gene IL33 and chronic myelogenous leukemia, BCR-ABL1 positive.